Perspective epidemiological survey of the treatment of CINV (Chemotherapy induced nausea and vomiting);Epidemiologia dei trattamenti dell'emesi in oncologia

Giornale Italiano di Farmacia Clinica

Volumn 19, Issue 4, 2005, Pages 359-365

[No Author Info available]

Author keywords

Adverse effects; Epidemiological study; Oncology

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CHLORPHENIRAMINE; CORTICOSTEROID; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ONDANSETRON; SEROTONIN 3 RECEPTOR; TROPISETRON;

CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA; EPIDEMIOLOGICAL DATA; GYNECOLOGY; HEALTH SURVEY; HEMATOLOGY; HUMAN; MEDICINE; NAUSEA; ONCOLOGY; REVIEW;

EID: 33644840147     PISSN: 11203749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. De Boer-Dennert M, De Wit R, Schmitz PI et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer, 1997; 76: 1055-61.
2. Gralla RJ, Osaba D, Kris MG et al. Recommendations for the use of antiemetics: evidence-based clinical practice guidelines. J Clin Oncol, 1999; 17: 2971-94.
3. Anonimous. 5HT3-receptor antagonists as antiemetics in cancer. Drug Ther Bull, 2005; 43: 57-62.
4. Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist, 2003; 8: 187-98.
5. Jantunen IT et al. An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer, 1997; 33: 66-74.
6. Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol, 2000; 18: 3409-22.
7. De Wit R. Current position of 5-HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics. Br J Cancer, 2003; 88: 1823-7.
8. Italian Group for Antiemetic Research. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Support Care Cancer, 2000; 8: 229-32.
9. Hickok JT, Poscoe JA, Morrow GR et al. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer, 2003; 97: 2880-6.
10. Glaus A, Knipping C, Morant R et al. Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer, 2004; 12: 708-15.
11. Grunberg SM, Deuson RR, Mavros P et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics: perception versus reality. Cancer, 2004; 100: 2261-8.
12. Morrow GR, Roscoe JA, Hickok JT at al. Nausea and emesis: evidence for a biobehavioral perspective. Support Care Cancer, 2002; 10: 96-105.
13. Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer, 2005; 13: 117-21.
14. Ihbe-Heffinger A, Ehlken B, Bernard R et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol, 2004; 15: 526-36.
15. Roscoe JA, Hickok JT, Morrow GR. Patient expectations as predictor of chemotherapy-induced nausea. Ann Behav Med, 2000; 22: 121-6.
16. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: Antiemesis. Version 1-2004, 1-2005, 1-2006. Sito web: http://www.nccn.org.
17. The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol, 2006; 17: 20-8.
18. Kaiser R, Sezer O, Papies A et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol, 2002; 20: 2805-11.
19. Babaoglu MO, Bayar B, Aynacioglu AS et al. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clin Pharmacol Ther, 2005; 78: 619-26.